跳至主要内容
临床试验/NCT03994926
NCT03994926终止早期 1 期

Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment

Battelle Memorial Institute1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2020年2月3日最近更新:
适应症
干预措施

试验速览

阶段
早期 1 期
状态
终止
入组人数
3
试验地点
1
主要终点
Change from baseline in Pupil Dilation

研究概览

简要总结

The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self-reported cannabis subjective effects, cognitive effects).

详细描述

The proposed project is a single-visit clinical laboratory study to evaluate the initial efficacy of an eye tracking sensor to detect cannabis-related impairment.

Participants will be experienced but not frequent cannabis users without evidence of heavy alcohol or illicit drug use or other physical or mental health illness. Participants will come in for one screening visit, and those who consent, are eligible, and enroll will complete one experimental laboratory session involving smoking of 50% of 1 active (approximately 4.0% THC) cannabis cigarette. Assessments will be collected after-cannabis smoking up to 4 hours. Participants will be sent home from the laboratory via taxi.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Willing to sign a confidentiality agreement stating the will not discuss study specifics, information or materials presented to them in the study with those not involved in the study;
  • Currently living in Baltimore City or Baltimore County, MD, or Investigator discretion;
  • Able to read, understand, and sign informed consent;
  • 18-55 years old;
  • Self-reports lifetime smoking of cannabis at least 10 times without any negative side effects;
  • Self-reports past-year smoking of cannabis at least 1 time but no more than 2 days per week on average;
  • Designation of Medically Healthy for Research by the Study Physician.
  • Agree to abstain from consuming alcohol for 10 hours and marijuana for 72 hour prior to the study visit

排除标准

  • BAC > 0.020% as measured by alcohol breathalyzer;
  • Meets DSM-5 criteria for any current Axis I disorder other than mild or moderate Cannabis Use Disorder;
  • Self-reported current desire to stop cannabis use, defined as 7 or greater on an 11-rung (scale of 0-10) on the Contemplation Ladder assessment;
  • Self-reported current asthma, chronic obstructive pulmonary disease, hypertension, cardiovascular disease or any other medical illness that precludes participation based on the clinical judgment of the Study Physician and Investigative Team;
  • Has difficulties with blood draws or poor venous access;
  • History of blood donation in the past 30 days or receiving blood products within the past 2 months prior to any experimental visit;
  • Investigator discretion due to self-reported use of medical cannabis or using cannabis for self-medication;
  • Among females, current pregnancy or lactation or attempting to get pregnant, or at risk of becoming pregnant, as defined as being sexually active with a male partner and not willing to use a reliable form of contraception;
  • Investigator discretion due to use of caffeine, over-the-counter (OTC) drugs, prescription drugs, alcohol, or physical/mental health history;
  • Positive urine drug screen for drugs included on the urine drug panel other than cannabis;
  • Acute illness (such as cold or flu) which will require participant to be rescheduled, if authorized by study PI;
  • Vital signs thought to be clinically significant by licensed medical professional;
  • Self-reported history or medical evidence of prior intravenous drug use; and
  • Investigator discretion due to medical, mental health, or substance use history.
  • Presence of implanted devices in the body (pacemaker etc)
  • Previously reported negative effects from the use of VR goggles or negative effects from the use of VR goggles during screening

研究组 & 干预措施

Experimental

Experimental

Directed smoking of about 3.6% THC cannabis cigarette

干预措施: Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye (Device)

Experimental

Experimental

Directed smoking of about 3.6% THC cannabis cigarette

干预措施: Cannabis cigarette - 4.0% THC (Drug)

结局指标

主要结局

Change from baseline in Pupil Dilation

时间窗: Before and after smoking (up to 240 minutes)

Change in pupil dilation in different lights will be measured by the eye tracking sensor

Change from baseline in Gaze Nystagmus

时间窗: Before and after smoking (up to 240 minutes)

Change in Gaze Nystagmus will be measured by the eye tracking sensor

Change from baseline in Lack of Convergence

时间窗: Before and after smoking (up to 240 minutes)

Change in Lack of Convergence will be measured by the eye tracking sensor

次要结局

  • Change from baseline in Cannabis Subjective Effects(Before and after smoking (up to 240 minutes post smoking))
  • Change from baseline in Digit Symbol Substitution Task(Before and after smoking (up to 240 minutes post smoking))
  • Plasma THC(Before and after smoking (9 timepoints up to 240 minutes post smoking))
  • Change from baseline in Four Choice Reaction Time Task(Before and after smoking (up to 240 minutes post smoking))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验